{
    "Trade/Device Name(s)": [
        "Access Cortisol",
        "Access Cortisol Assay"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K223038",
    "Predicate Device Reference 510(k) Number(s)": [
        "K050202"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGR"
    ],
    "Summary Letter Date": "February 8, 2023",
    "Summary Letter Received Date": "September 29, 2022",
    "Submission Date": "January 30, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1205"
    ],
    "Regulation Name(s)": [
        "Cortisol (hydrocortisone and hydroxycorticosterone) test system"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Cortisol"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Competitive binding immunoenzymatic assay",
        "Automated immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Analyzer",
        "Buffer",
        "Substrate"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access Cortisol chemiluminescent immunoassay for quantitation of cortisol in serum, plasma (heparin, EDTA), and urine on DxI 9000 analyzer",
    "Indications for Use Summary": "Quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA), and urine for diagnosis and treatment of adrenal gland disorders using Access Immunoassay Systems.",
    "fda_folder": "Clinical Chemistry"
}